Home Capital Broker's Calls

Here's why this Chinese pharmaceutical firm is hard to ignore

Stanislaus Jude Chan
Stanislaus Jude Chan5/21/2018 11:15 AM GMT+08  • 2 min read
Here's why this Chinese pharmaceutical firm is hard to ignore
SINGAPORE (May 21): UOB Kay Hian is keeping its “buy” call on Tianjin Zhong Xin Pharmaceutical Group Corporation (TJZX) with an unchanged target price of US$1.72 – representing an upside of 43%.
Font Resizer
Share to WhatsappShare to FacebookShare to LinkedInMore Share
Scroll to top
Follow us on Facebook and join our Telegram channel for the latest updates.

SINGAPORE (May 21): UOB Kay Hian is keeping its “buy” call on Tianjin Zhong Xin Pharmaceutical Group Corporation (TJZX) with an unchanged target price of US$1.72 – representing an upside of 43%.

Shares in the Chinese pharmaceutical firm have already climbed some 20% to US$1.20 as at 10.23am on Monday since it announced a stellar 1Q18 on Apr 27.

However, UOB notes that the spread between TJZX’s S-shares listed on the Singapore Exchange (SGX) and its A-shares listed on the Shanghai Stock Exchange (SSE) have been steadily widening since May.

For more insights on corporate trends...
Sign In or Create an account to access our premium content.
Subscription Entitlements:
Less than $9 per month
Unlimited access to latest and premium articles
3 Simultaneous logins across all devices
Bonus unlimited access to online articles and virtual newspaper on The Edge Malaysia (single login)
×
Loading next article...
The Edge Singapore
Download The Edge Singapore App
Google playApple store play
Keep updated
Follow our social media
Subscribe to The Edge Singapore
Get credible investing ideas from our in-depth stock analysis, interviews with key executives, corporate movements coverage and their impact on the market.
© 2022 The Edge Publishing Pte Ltd. All rights reserved.
Unlock unlimited access to premium articles with less than $9 per month. Subscribe Now